Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). - Mollica V; Massari F; Fujita K; Giannatempo P; Grande E; Büttner T; Bourlon MT; Taha T; Fukuokaya W; Myint ZW; Pichler R; Binz K; et al. (Cancer immunology, immunotherapy : CII, 2026)